Clinical Topics

Metformin Promising for Improving Prostate Cancer Survival

by U.S. Medicine

September 9, 2018

MADISON, WI—Metformin, a commonly used drug for patients with Type 2 diabetes mellitus (DM), has shown promise in helping to treat prostate cancer (PCa), according to a new study.

The report in the Journal of Urology posited that metformin plus androgen deprivation therapy (ADT) might be beneficial in combination. To do that, a research team from the William S. Middleton Memorial Veterans Hospital and the University of Wisconsin-Madison performed a retrospective cohort of patients with advanced PCa.1

The investigators used the national VA database to identify all men diagnosed with PCa between 2000-2008 who were treated with ADT with follow-up through May of 2016. Excluded from the study were patients who had received ADT for six months or less or who had undergone the therapy concurrent with localized radiation.

In the cohort after exclusions were 87,344 patients divided into three cohorts: 61% were no DM, 22% were DM no metformin, and 17% were DM on metformin. Hazard ratios were calculated for overall survival (OS), skeletal-related events (SRE) and cancer-specific survival (CSS).

Results indicated that OS showed improved survival in DM on metformin (HR 0.82, 95% CI 0.78-0.86) vs. DM no metformin (HR 1.03, 95% CI 0.99-1.08) with no DM as referent group.

In addition, the study team noted, research revealed HR 0.82 (95% CI 0.72-0.93) for DM on metformin, while Cox proportional hazards analysis for CSS showed improved survival in DM on metformin (HR 0.70, 95% CI 0.64-0.77) vs. DM with no metformin (HR 0.93, 95% CI 0.85- 1.00), using no DM as a referent group.

“Metformin use in veterans with PCa receiving ADT is associated with improved oncologic outcomes,” study authors concluded. “This association should be evaluated in a prospective clinical trial.”

1. Richards KA, Liou JI, Cryns VL, Downs TM, Abel EJ, Jarrard DF. Metformin Use Is Associated with Improved Survival in Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy. J Urol. 2018 Jun 22. pii: S0022-5347(18)43412-X. doi: 10.1016/j.juro.2018.06.031. [Epub ahead of print] PubMed PMID: 29940252.


Comments are closed here.


Related Articles

Racial Disparities Found in BRCA Testing, Counseling

DURHAM, NC—Despite increases in BRCA mutation testing, racial/ethnic disparities in counseling and testing have persisted for decades, a study argued. The review published in the Journal of Racial and Ethnic Health Disparities said its purpose... View Article

VA Guideline Addresses Dental Management of Head/Neck Cancer Patients

SAN FRANCISCO—Few protocols have been published for the dental management of patients with head and neck cancer to prevent complications from head and neck radiation therapy, according to a new study.  The report in the... View Article


U.S. Medicine Recommends


More From oncology

Oncology

Racial Disparities Found in BRCA Testing, Counseling

DURHAM, NC—Despite increases in BRCA mutation testing, racial/ethnic disparities in counseling and testing have persisted for decades, a study argued. The review published in the Journal of Racial and Ethnic Health Disparities said its purpose... View Article

Oncology

VA Guideline Addresses Dental Management of Head/Neck Cancer Patients

SAN FRANCISCO—Few protocols have been published for the dental management of patients with head and neck cancer to prevent complications from head and neck radiation therapy, according to a new study.  The report in the... View Article

Oncology

Patients Treated with Thiopurines Have Higher Skin Cancer Mortality

PHILADELPHIA—Treatment with thiopurines is associated with an increased risk of squamous cell carcinoma of the skin in patients with inflammatory bowel diseases. An article in Clinical Gastroenterology and Hepatology discussed results of a study that... View Article

Oncology

Overcoming Radiation Resistant Prostate Cancer

LOS ANGELES—For nearly half of the patients with localized advanced prostate cancer, radiation therapy is the primary intervention and standard of care for recurrent disease following surgery. The problem is that nearly 30% to 50%... View Article

Oncology

JAK Enzymes Can Treat Leukemia, Lymphoma

NASHVILLE, TN—Precision oncology prescribes the use of molecularly-targeted therapy directed by identification of genomic alterations. A new study suggested the approach is particularly applicable to neoplasms that are resistant to standard cytotoxic chemotherapy, such as... View Article

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up